RHHVF : Summary for ROCHE HLDGS AG GENUSSCHEINE NPV - Yahoo Finance

U.S. Markets open in 36 mins.

Roche Holding AG (RHHVF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
244.550.00 (0.00%)
At close: 2:59PM EST
People also watch
NVSEFNSRGFRHHBFHBCYFGLAXF
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close244.55
Open244.15
Bid0.00 x
Ask0.00 x
Day's Range241.59 - 244.55
52 Week Range216.45 - 256.54
Volume544
Avg. Volume3,672
Market Cap207.62B
BetaN/A
PE Ratio (TTM)21.78
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    Roche says Phase II trial supports twin treatment for kidney cancer

    Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.

  • These Are The First Immune-System Cancer Drugs OK'd By FDA
    Investor's Business Daily3 days ago

    These Are The First Immune-System Cancer Drugs OK'd By FDA

    A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.

  • AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink
    Investor's Business Daily3 days ago

    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink

    Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.